CombiPatch / Climara Pro and Testosterone: What You Need to Know Before Combining Them

What is the interaction between CombiPatch or Climara Pro and testosterone?

The combination of a transdermal estrogen-progestin patch with testosterone therapy produces a pharmacodynamic interaction, not a pharmacokinetic one. Neither drug meaningfully alters the other's metabolism through CYP450 enzymes at typical doses. What does happen is an overlap of physiological effects on red blood cells, lipid fractions, and androgen-sensitive tissues.

Testosterone raises hematocrit, suppresses HDL cholesterol, and acts on androgen receptors throughout the body. The progestin in each patch adds to this picture differently depending on which molecule you are using.

How CombiPatch and Climara Pro differ in terms of androgenicity

CombiPatch delivers estradiol 0.05 mg and norethindrone acetate 0.14 mg or 0.25 mg per day. Norethindrone acetate has moderate androgenic activity at the androgen receptor, roughly 15% relative to methyltestosterone in receptor-binding assays.

Climara Pro delivers estradiol 0.045 mg and levonorgestrel 0.015 mg per day. Levonorgestrel has substantially higher androgen receptor affinity than norethindrone acetate, roughly 40-70% relative binding affinity compared to testosterone in receptor studies. This matters clinically: a woman already using testosterone who switches to Climara Pro from a less androgenic progestin may notice worsened acne, oilier skin, or accelerated facial hair growth because the total androgen load at the receptor level is higher.

What this means for your choice of patch

If you are postmenopausal and using or planning to use testosterone for hypoactive sexual desire disorder (HSDD) or general androgen deficiency symptoms, the choice between these two patches is not trivial. CombiPatch's norethindrone component contributes less androgenic receptor stimulation than Climara Pro's levonorgestrel, making it the more commonly preferred option when testosterone is co-prescribed, though no head-to-head randomized trial has directly compared the two in this exact context. This is one area where clinical extrapolation from receptor pharmacology guides practice rather than direct female-specific trial data.

Why does the progestin component matter when you are taking testosterone?

Both patches are indicated for women with an intact uterus. The progestin prevents endometrial hyperplasia from unopposed estradiol. That purpose is unchanged when you add testosterone. But the androgen receptor activity of the progestin now stacks with the androgen receptor activity of exogenous testosterone, and that stacking has real-world consequences.

Lipid effects

Testosterone alone lowers HDL cholesterol by an average of 5-10% in women using physiologic doses. Levonorgestrel also suppresses HDL, while norethindrone acetate has a smaller but still measurable effect. Estradiol, delivered transdermally, partially counteracts this by raising HDL and lowering LDL. The net direction of lipid change in any individual woman depends on the balance of these effects, her baseline lipid profile, and the testosterone dose she uses.

A fasting lipid panel before starting the combination and at 3 and 6 months after is the standard of care recommended by The Menopause Society's 2022 position statement on testosterone therapy for menopausal women.

Polycythemia and hematocrit

Testosterone increases erythropoiesis, raising hematocrit and hemoglobin. In men, this is a well-recognized adverse effect at supratherapeutic doses, but women are not immune. A hematocrit above 50% in a woman on testosterone warrants dose reduction or temporary discontinuation. The combination patch does not significantly worsen this risk on its own, but norethindrone acetate has weak androgenic activity that adds marginally to the red cell stimulation. A baseline CBC and repeat at 6 months is reasonable when combining testosterone with any hormonal contraceptive or HRT regimen.

Androgenic skin and hair effects

Women taking testosterone alongside Climara Pro may find that the additive androgenic signaling accelerates androgenic alopecia or worsens hormonal acne more than they would expect from testosterone alone. This is a direct pharmacodynamic consequence of levonorgestrel's androgenic receptor activity. Women with a personal or family history of female pattern hair loss or PCOS should discuss this risk explicitly before choosing Climara Pro over a patch with a less androgenic progestin.

CYP450 and drug metabolism: Is there a pharmacokinetic interaction?

Standard transdermal delivery bypasses hepatic first-pass metabolism, which is one reason combination patches are preferred over oral hormones in many women with metabolic concerns. Because the hormones in CombiPatch and Climara Pro do not substantially pass through the gut wall and liver before reaching circulation, the CYP3A4 induction and inhibition that matter so much for oral hormones are largely irrelevant here.

Testosterone itself is a CYP3A4 substrate but is not a meaningful inducer or inhibitor at physiologic female doses. FDA prescribing information for transdermal testosterone products does not flag estrogen or progestin co-administration as a pharmacokinetic concern requiring dose adjustment.

There is one nuance worth knowing: if a woman is also taking a CYP3A4 inhibitor such as ketoconazole, fluconazole, or certain antiretrovirals, testosterone levels could rise unpredictably. The combination patch hormones could be similarly affected. That is a separate drug-drug interaction but one worth screening for at the time of prescribing.

P-glycoprotein (P-gp) considerations

Testosterone is not a significant P-gp substrate or inhibitor. Norethindrone and levonorgestrel have some P-gp interaction data in in vitro models, but clinical significance at the doses delivered by the patches is considered negligible based on current evidence. Women taking P-gp substrates with narrow therapeutic windows (digoxin, certain immunosuppressants) should be assessed individually, but the combination patch plus testosterone pairing itself does not create a P-gp problem.

Who this combination is and is not right for

Women who may benefit most

Postmenopausal women with an intact uterus who have both vasomotor symptoms and HSDD or low libido are the primary candidates. The Menopause Society 2022 position statement concludes there is Level I evidence supporting testosterone therapy for postmenopausal HSDD. CombiPatch or Climara Pro addresses vasomotor symptoms and protects the endometrium; testosterone addresses sexual function. The combination is clinically logical when both symptom domains are present.

Perimenopausal women also sometimes experience declining testosterone levels alongside estrogen fluctuation. If a perimenopausal woman has an intact uterus and is using a combination patch for symptom control, adding testosterone for HSDD follows the same monitoring principles.

Women who need extra caution or should avoid this combination

Women with any of the following should have a detailed risk-benefit conversation before combining these agents:

• Polycythemia vera or baseline hematocrit above 48%
• Severe dyslipidemia, particularly low HDL or very high LDL
• Active liver disease (though transdermal delivery reduces hepatic burden)
• Hormone-sensitive cancers, including breast or endometrial cancer
• PCOS with existing hyperandrogenism, where adding exogenous testosterone may worsen androgenic symptoms
• A history of female pattern hair loss, as the androgenic progestins and testosterone together may accelerate this

Women with PCOS in perimenopause occupy a particularly complex position. Many have residual hyperandrogenism from their reproductive years; adding testosterone on top of a more androgenic patch like Climara Pro could amplify acne, hirsutism, or hair thinning. CombiPatch with its less androgenic progestin is a more cautious starting point if testosterone is medically indicated.

Pregnancy, lactation, and contraception: critical safety information

Both CombiPatch and Climara Pro are contraindicated in pregnancy. Neither is approved as a contraceptive, and both carry warnings that they must not be used by women who are or may become pregnant. The FDA labeling for CombiPatch states there is no indication for the product in premenopausal women outside of specific approved contexts, and it should be stopped immediately if pregnancy is confirmed.

Testosterone is also contraindicated in pregnancy. Exogenous testosterone can virilize a female fetus, causing clitoral enlargement and labial fusion in female fetuses exposed in the first trimester. This is a serious teratogenic risk. Any woman of reproductive potential who is prescribed testosterone must use reliable contraception.

Who might still have reproductive potential?

Perimenopausal women who have not completed 12 consecutive months without a menstrual period remain potentially fertile, even with irregular cycles. If you are in perimenopause and your clinician is considering testosterone alongside your combination patch, contraception is not optional. A barrier method, copper IUD, or progestin-only IUD should be discussed. The levonorgestrel IUD provides endometrial protection and contraception simultaneously, though it would change the rationale for the combination patch's progestin component.

Lactation

Testosterone is not recommended during breastfeeding. Data on transfer into human milk are limited, but androgen transfer to a nursing infant carries theoretical risk of virilization and disruption of neonatal hormone axes. The LactMed database at NIH advises that testosterone use is generally incompatible with breastfeeding. CombiPatch and Climara Pro are not indicated in lactating women either, as exogenous estrogen can suppress milk production.

How to monitor safely if you are taking both

Monitoring is not a formality. The specific schedule recommended for women combining testosterone with hormonal menopause therapy includes:

1. Baseline labs before starting testosterone: Total and free testosterone, SHBG, CBC with hematocrit, fasting lipid panel, and liver function tests.
2. At 6 weeks or 3 months: Repeat total and free testosterone to confirm levels are in the physiologic female range (total testosterone typically 15-70 ng/dL in postmenopausal women, though laboratory reference ranges vary). Dose adjustment should target the lower half of premenopausal female reference ranges per The Menopause Society 2022 guidance.
3. At 6 months: Repeat CBC, lipid panel, and testosterone levels.
4. Ongoing annual review: Assess for androgenic side effects (acne, hirsutism, voice changes, clitoral enlargement). Any voice change or clitoral enlargement suggests supraphysiologic dosing and the testosterone should be reduced or stopped.

SHBG levels deserve specific attention in women on transdermal estradiol. Transdermal estrogen raises SHBG less than oral estrogen does, which means more testosterone remains free and biologically active. A woman switching from oral estrogen to a patch while continuing the same testosterone dose may notice stronger androgenic effects because the free testosterone fraction increases when SHBG falls.

Testosterone formulations currently used in postmenopausal women in the US

No testosterone product carries an FDA approval specifically for women in the United States as of 2025. Clinicians prescribe off-label using compounded testosterone creams or gels, or use male-approved products (AndroGel, Testim, Axiron) at doses approximately one-tenth of the male dose. A 2019 systematic review and consensus statement published in The Lancet Diabetes and Endocrinology reviewed evidence from 36 randomized controlled trials and concluded that testosterone was effective for HSDD in postmenopausal women, with a favorable safety profile at physiologic doses over 24 weeks.

The absence of an approved female product is a genuine evidence gap. Most pharmacokinetic data on testosterone in women come from studies using male-formulated products at reduced doses. Compounded preparations vary in absorption and potency between pharmacies. Women should ask their prescribing clinician which specific preparation and dose is being used, and ensure monitoring accounts for the variability inherent in compounded products.

Talking to your clinician: questions worth asking

Before combining testosterone with your combination patch, bring these questions to your appointment:

• Which patch is right for me given that I am starting testosterone, CombiPatch or Climara Pro, and why?
• What testosterone formulation will you prescribe, at what dose, and how do I apply it to avoid skin transfer to partners or children?
• What symptoms should make me call you before my scheduled follow-up?
• Will my insurance cover the testosterone, and if not, what is the cost of the compounded version at local pharmacies?
• How long do you plan to continue testosterone before reassessing whether I still need it?

The combination of a transdermal estrogen-progestin patch with physiologic-dose testosterone is used by many postmenopausal women with good tolerability when monitored appropriately. The pharmacodynamic interaction is real but manageable. Choosing the less androgenic patch (CombiPatch) when your total androgen burden is already being increased by exogenous testosterone is a clinically sound preference, supported by receptor pharmacology even in the absence of a direct comparative trial.